Immix Biopharma, Inc. IMMX Operating Lease Liability Payments - 2024 (Lessee)

Operating Lease Liability Payments - 2024 (Lessee) at other companies

Allogene TherapeuticsALLO

——

PrecigenPGEN

——

Artiva Biotherapeutics, Inc.ARTV

——

ImmunityBio, Inc.IBRX

——

Operating income-$10.8M-131%

Net income-$10.1M-122%

EPS (diluted)-$0.18-20.0%

Cash & equivalents$79.3M+398%

Total debt$1.0M-2.0%

Total equity$84.4M+779%

Total assets$95.8M+382%

Operating cash flow-$9.8M-483%

CapEx$32.5K-52.0%

Free cash flow-$9.9M-462%

Market cap$691.97M+1,008%

Enterprise value$613.75M+1,190%

Return on equity-74.4%-18.6pp

Debt / equity0×-0.1×

Current ratio8.8×+7.0×

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Immix Biopharma, Inc.'s operating lease liability payments - 2024 (lessee)?: Immix Biopharma, Inc. (IMMX) reported operating lease liability payments - 2024 (lessee) of $163.87K in Q1 2026.
How has Immix Biopharma, Inc.'s operating lease liability payments - 2024 (lessee) changed year-over-year?: Immix Biopharma, Inc.'s operating lease liability payments - 2024 (lessee) increased by 3.5% year-over-year, from $158.33K to $163.87K.